Iovance Biotherapeutics (IOVA) Raw Materials (2024 - 2025)
Iovance Biotherapeutics (IOVA) posted quarterly Raw Materials of $37.9 million for Q1 2025, up 581.14% year-over-year from $5.6 million in Q1 2024, and up 36.65% quarter-over-quarter from $27.7 million in Q4 2024.
Powered by 
Analysis
Iovance Biotherapeutics (IOVA) Raw Materials (2024 - 2025) Analysis & Trends
Iovance Biotherapeutics (IOVA) has reported Raw Materials for 2 consecutive years, with $37.9 million the latest figure, recorded in Q1 2025.
- In Q1 2025, Raw Materials rose 581.14% year-over-year to $37.9 million; the TTM figure through Mar 2025 stood at $37.9 million (up 581.14% YoY), while the FY2024 annual figure was $27.7 million, changed N/A from the prior year.
- Raw Materials climbed to $37.9 million in Q1 2025 per IOVA's latest filing, from $27.7 million in the prior quarter.
- Across five years, Raw Materials topped out at $37.9 million in Q1 2025 and bottomed at $5.6 million in Q1 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Iovance Biotherapeutics | 3.95 Bn | 3.66 Bn | 55.72 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2025 | 37.91 Mn |
| Dec 31, 2024 | 27.74 Mn |
| Mar 31, 2024 | 5.57 Mn |